Related Experiment Video
Updated: May 17, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance
1Biomedical Science Research Institute, University of Ulster, Cromore Road, Coleraine, Londonderry BT52 1SA, Northern Ireland.
British Journal of Cancer
|October 18, 2012
Summary
Hypoxia increases RUNX2 expression in prostate cancer cells, promoting resistance to apoptosis and cancer progression by upregulating Bcl-2. This RUNX2-mediated mechanism drives a more malignant phenotype.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Hypoxia promotes prostate cancer cell invasiveness and apoptosis resistance.
- Upregulation of RUNX2 and Bcl-2 observed in hypoxia-selected LNCaP cells.
Purpose of the Study:
- Investigate the biological mechanism linking hypoxia, RUNX2, and apoptosis resistance in prostate cancer.
- Determine the role of RUNX2 in regulating Bcl-2 expression and apoptosis resistance.
Main Methods:
- Examined hypoxia's effect on RUNX2 expression in vitro and in vivo.
- Utilized RUNX2 overexpression and siRNA in LNCaP cells.
- Assessed cell viability, apoptosis resistance, Bcl-2 levels, and gene expression.
- Chromatin immunoprecipitation (ChIP) and reporter assays confirmed RUNX2-Bcl-2 interaction.
Main Results:
- Hypoxia increased RUNX2 expression in LNCaP cells and tumors.
- RUNX2 overexpression enhanced cell viability and apoptosis resistance to treatments.
- RUNX2 directly upregulated Bcl-2 expression, confirmed by ChIP assays.
- Other apoptosis-associated genes were also upregulated by RUNX2.
Conclusions:
- RUNX2 is a key mediator of apoptosis resistance in prostate cancer under hypoxic conditions.
- Increased RUNX2 expression contributes to a more malignant, apoptosis-resistant prostate cancer phenotype.
- RUNX2 modulates apoptosis-associated factors, notably Bcl-2, driving disease progression.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...